Japan university reveals more claims of fabricated drug data

A Japanese university Wednesday said it would retract a study that touted the effectiveness of a blood pressure drug made by Swiss pharmaceutical giant Novartis because it was based on fabricated data.

The move was the latest chapter in a growing scandal over allegations that bogus data were used in a string of Japanese university studies for the drug Valsartan which exaggerated its effectiveness in preventing strokes and angina.

On Wednesday, Tokyo's Jikei University School of Medicine said it would retract research that appeared in respected medical journal The Lancet six years ago.

"We will report the conclusions of our investigation to Lancet so the study can be withdrawn," a university spokesman told AFP.

The school's probe concluded that the research, led by one of Jikei's professors, relied on data analysis by an unnamed former Novartis employee, who was also involved in at least one other school's research which has been thrown into question.

The fresh allegations come less than two weeks after Japan's said it was very likely that tests for Valsartan were based on incomplete clinical data.

Jikei University's probe also found it had received about $85,000 worth of grants from Novartis for the study, pointing to a , it said.

The local unit of Novartis could not be immediately reached for comment Wednesday.

On Monday, Yoshiyasu Ninomiya, head of the Swiss firm's Japanese unit, apologised for the involvement of an employee in university studies.

But he stood by other tests that said Valsartan is effective at preventing strokes and angina, as well as controlling .

Novartis sells the drug under the name Diovan in Japan, where it is one of the most commonly prescribed drugs on the market. It is licensed for use in more than 100 countries.

Three other Japanese universities are investigating similar claims, local media reported.

add to favorites email to friend print save as pdf

Related Stories

Novartis chief sees sales dip until mid-2013

Oct 07, 2012

Swiss pharmaceutical giant Novartis said Sunday the expiry of a US patent for its leading hypertension drug Diovan caused a drop in turnover that could last into the first half of 2013.

Britain snubs costly Novartis blood cancer drug

Feb 13, 2013

British health authorities said on Wednesday they would not recommend Jakavi, a drug produced by Swiss pharmaceutical company Novartis to treat a rare form of blood cancer, deeming it too expensive.

Recommended for you

Express Scripts turns to AbbVie in huge hepatitis C deal

Dec 22, 2014

The nation's largest pharmacy benefits manager is throwing its weight into the fight over high-cost hepatitis C drugs with a coverage restriction that might ultimately lower prices and improve patient access ...

FDA OKs Cubist antibiotic for serious infections

Dec 20, 2014

The Food and Drug Administration has approved a new medicine to fight complex infections in the abdomen and urinary tract, the fourth antibiotic the agency has approved since May.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.